Community Research Initiative of New England
10
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
20.0%
2 terminated/withdrawn out of 10 trials
80.0%
-6.5% vs industry average
70%
7 trials in Phase 3/4
75%
6 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic
Role: lead
FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment
Role: lead
Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r
Role: lead
Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors
Role: lead
BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.
Role: lead
BRAVO: Background Regimen of Raltegravir on Virologic Outcome
Role: lead
A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells
Role: lead
BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)
Role: lead
An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent
Role: lead
A Study to Evaluate the Effect of Cimetidine on CD4 Lymphocyte Counts in HIV Infection
Role: lead
All 10 trials loaded